Targeting cancer metabolism has emerged as a promising therapeutic strategy, as cancer cells exhibit distinct metabolic requirements compared to normal cells. Cancer cells often rely on aerobic glycolysis, a process known as the Warburg effect, which involves increased glucose uptake and lactate production. This metabolic shift is critical for cancer cell proliferation and survival, making it an attractive target for therapy. However, targeting metabolic pathways poses challenges due to the shared metabolic needs of normal and cancer cells. Despite this, some cancer therapies have successfully targeted specific metabolic dependencies, such as those involving glucose and glutamine metabolism. Metabolic enzymes, which catalyze the interconversion of metabolites, are key targets for cancer therapy. Drugs like metformin, which inhibits mitochondrial complex I, have shown potential in cancer treatment by inducing energy stress and altering metabolic pathways. However, the effectiveness of such therapies depends on the specific metabolic profile of the tumor. For example, metformin may benefit patients with high levels of insulin-like growth factor (IGF), but its effects on cancer stem cells and other tissues require further investigation. Recent advances in metabolite profiling and imaging techniques, such as FDG-PET, have provided insights into tumor metabolism and helped identify potential therapeutic targets. These tools are crucial for understanding how metabolic pathways are regulated in cancer cells and for developing more effective therapies. Additionally, the development of drugs targeting specific metabolic enzymes, such as those involved in glycolysis and the tricarboxylic acid (TCA) cycle, has shown promise in preclinical models. Despite these advancements, challenges remain in translating these findings into effective clinical therapies. The complexity of metabolic networks and the potential for resistance to targeted therapies highlight the need for a deeper understanding of cancer metabolism. However, the potential of targeting metabolic enzymes offers a promising avenue for improving cancer treatment by selectively disrupting the metabolic processes that support tumor growth and survival.Targeting cancer metabolism has emerged as a promising therapeutic strategy, as cancer cells exhibit distinct metabolic requirements compared to normal cells. Cancer cells often rely on aerobic glycolysis, a process known as the Warburg effect, which involves increased glucose uptake and lactate production. This metabolic shift is critical for cancer cell proliferation and survival, making it an attractive target for therapy. However, targeting metabolic pathways poses challenges due to the shared metabolic needs of normal and cancer cells. Despite this, some cancer therapies have successfully targeted specific metabolic dependencies, such as those involving glucose and glutamine metabolism. Metabolic enzymes, which catalyze the interconversion of metabolites, are key targets for cancer therapy. Drugs like metformin, which inhibits mitochondrial complex I, have shown potential in cancer treatment by inducing energy stress and altering metabolic pathways. However, the effectiveness of such therapies depends on the specific metabolic profile of the tumor. For example, metformin may benefit patients with high levels of insulin-like growth factor (IGF), but its effects on cancer stem cells and other tissues require further investigation. Recent advances in metabolite profiling and imaging techniques, such as FDG-PET, have provided insights into tumor metabolism and helped identify potential therapeutic targets. These tools are crucial for understanding how metabolic pathways are regulated in cancer cells and for developing more effective therapies. Additionally, the development of drugs targeting specific metabolic enzymes, such as those involved in glycolysis and the tricarboxylic acid (TCA) cycle, has shown promise in preclinical models. Despite these advancements, challenges remain in translating these findings into effective clinical therapies. The complexity of metabolic networks and the potential for resistance to targeted therapies highlight the need for a deeper understanding of cancer metabolism. However, the potential of targeting metabolic enzymes offers a promising avenue for improving cancer treatment by selectively disrupting the metabolic processes that support tumor growth and survival.